[{"id":"825a0e35-0b45-4a5a-bf8e-33ed379203ac","acronym":"","url":"https://clinicaltrials.gov/study/NCT05869279","created_at":"2023-05-22T16:05:43.593Z","updated_at":"2024-07-02T16:35:05.947Z","phase":"Phase 1/2","brief_title":"Allogeneic CARCIK-CD19 in Adults/Pediatric B-cell NHL or Chronic Lymphocytic Leukemia","source_id_and_acronym":"NCT05869279","lead_sponsor":"Fondazione Matilde Tettamanti Menotti De Marchi Onlus","biomarkers":" BCL2","pipe":" | ","alterations":" MYC rearrangement • BCL2 rearrangement","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CARCIK-CD19"],"overall_status":"Recruiting","enrollment":" Enrollment 29","initiation":"Initiation: 12/01/2023","start_date":" 12/01/2023","primary_txt":" Primary completion: 09/01/2026","primary_completion_date":" 09/01/2026","study_txt":" Completion: 09/01/2027","study_completion_date":" 09/01/2027","last_update_posted":"2024-05-03"},{"id":"121b7ba8-b6d4-4942-b973-8ae7d17ebde9","acronym":"CARCIK","url":"https://clinicaltrials.gov/study/NCT03389035","created_at":"2021-01-18T16:43:34.474Z","updated_at":"2024-07-02T16:35:49.003Z","phase":"Phase 1/2","brief_title":"Transposon-manipulated Allogeneic CARCIK-CD19 Cells in Pediatric and Adult Patients With r/r ALL Post HSCT","source_id_and_acronym":"NCT03389035 - CARCIK","lead_sponsor":"Fondazione Matilde Tettamanti Menotti De Marchi Onlus","biomarkers":" CD19","pipe":" | ","alterations":" CD19 expression","tags":["CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CARCIK-CD19"],"overall_status":"Completed","enrollment":" Enrollment 21","initiation":"Initiation: 12/20/2017","start_date":" 12/20/2017","primary_txt":" Primary completion: 03/31/2021","primary_completion_date":" 03/31/2021","study_txt":" Completion: 12/30/2022","study_completion_date":" 12/30/2022","last_update_posted":"2023-05-04"},{"id":"1c2941e0-03e1-46bf-89f8-c0e052ecf93a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05252403","created_at":"2022-02-23T19:55:05.099Z","updated_at":"2024-07-02T16:35:49.011Z","phase":"Phase 2","brief_title":"Residual Disease Driven Strategy for CARCIK (CD19) in Adults/Pediatric BCP-ALL","source_id_and_acronym":"NCT05252403","lead_sponsor":"Fondazione Matilde Tettamanti Menotti De Marchi Onlus","biomarkers":" CD19","pipe":" | ","alterations":" CD19 positive • CD19 expression","tags":["CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 positive • CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CARCIK-CD19"],"overall_status":"Recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 12/01/2021","start_date":" 12/01/2021","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2023-05-04"}]